Poll

Poll results: Will you use biosimilars in your ophthalmic practice?

Results from our recent poll indicate that many ophthalmologists (63%) plan to use biosimilars in their clinical practice.

Ophthalmology Times® polled our audience with the following question from September 26, 2022 to October 10, 2022:​ Will you use biosimilars in your ophthalmic practice?

The poll appeared on OphthalmologyTimes.com and was promoted in our e-newsletters during this time. Results show a majority of ophthalmologists plan to use biosimilars in their practice.

37 responses were recorded, in total. Of these:

23% responded, "Yes, I plan to use biosimilars in my practice."

14% responded, "No, I do not plan to use biosimilars in my practice."

.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.